Fundz

Hexagon Bio raises $62M in Series C funding led by The Column Group. The funds will support the Phase 1 clinical trial of HEX-360 and enhance its proprietary platform.

PRIVATEOct 26, 2026

Amount Raised

$62 Million

Round Type

Series C

Menlo ParkBiotechnology

Investors

Canada Pension Plan Investment Board8VCDeviation CapitalNextech InvestThe Column Group

Description

Hexagon Bio, a Menlo Park, CA-based biopharmaceutical company, raised $62M in Series C funding. The round was led by The Column Group, with participation from several investors. The company plans to use the funds for its Phase 1 clinical trial of HEX-360 and to advance additional payload mechanisms. CEO Maureen Hillenmeyer leads the effort to leverage their proprietary platform for ADC payloads.

Who to call at Hexagon Bio Inc., and when

A new round usually means Hexagon Bio Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Hexagon Bio Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hexagon Bio Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hexagon Bio Inc.. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Hexagon Bio Inc.

Location

1490 O'BRIEN DRIVE

Menlo Park, California, United States

About

Hexagon Bio is a data-driven biopharma company developing targeted small molecule therapeutics. Our proprietary platform combines data science, genomics, synthetic biology, chemistry and automation to discover potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Hexagon Bio Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMike B., Chief Growth Officer and Board of Direc… hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Hexagon Bio Inc.'s next move

See what Strategic adds

Hexagon Bio Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.